Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.
